Literature DB >> 34279771

Defective Autophagy and Mitophagy in Alzheimer's Disease: Mechanisms and Translational Implications.

Jie Chen1, Hai-Jun He2, Qianqian Ye2, Feifei Feng2, Wen-Wen Wang3, Yingying Gu4, Ruiyu Han5, Chenglong Xie6,7,8.   

Abstract

The main histopathology of Alzheimer's disease (AD) is featured by the extracellular accumulation of amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles (NFT) in the brain, which is likely to result from co-pathogenic interactions among multiple factors, e.g., aging or genes. The link between defective autophagy/mitophagy and AD pathologies is still under investigation and not fully established. In this review, we consider how AD is associated with impaired autophagy and mitophagy, and how these impact pathological hallmarks as well as the potential mechanisms. This complicated interplay between autophagy or mitophagy and histopathology in AD suggests that targeting autophagy or mitophagy probably is a promising anti-AD drug candidate. Finally, we review the implications of some new insights for induction of autophagy or mitophagy as the new therapeutic way that targets processes upstream of both NFT and Aβ plaques, and hence stops the neurodegenerative course in AD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Autophagy; Dementia; Mitophagy; Molecular mechanism

Mesh:

Substances:

Year:  2021        PMID: 34279771     DOI: 10.1007/s12035-021-02487-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  106 in total

1.  Make dementia a public health priority in India.

Authors:  Rabindra Nath Sinha
Journal:  Indian J Public Health       Date:  2011 Apr-Jun

Review 2.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

3.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Authors:  Lawrence S Honig; Bruno Vellas; Michael Woodward; Mercè Boada; Roger Bullock; Michael Borrie; Klaus Hager; Niels Andreasen; Elio Scarpini; Hong Liu-Seifert; Michael Case; Robert A Dean; Ann Hake; Karen Sundell; Vicki Poole Hoffmann; Christopher Carlson; Rashna Khanna; Mark Mintun; Ronald DeMattos; Katherine J Selzler; Eric Siemers
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

Review 4.  Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship.

Authors:  Peter T Nelson; Heiko Braak; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-01       Impact factor: 3.685

5.  Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Authors:  Michael F Egan; James Kost; Pierre N Tariot; Paul S Aisen; Jeffrey L Cummings; Bruno Vellas; Cyrille Sur; Yuki Mukai; Tiffini Voss; Christine Furtek; Erin Mahoney; Lyn Harper Mozley; Rik Vandenberghe; Yi Mo; David Michelson
Journal:  N Engl J Med       Date:  2018-05-03       Impact factor: 91.245

Review 6.  Neuropathology of Alzheimer's disease.

Authors:  Daniel P Perl
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 7.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Giancarlo Logroscino
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

Review 8.  Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.

Authors:  D Allan Butterfield; Barry Halliwell
Journal:  Nat Rev Neurosci       Date:  2019-03       Impact factor: 38.755

Review 9.  Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease.

Authors:  Miia Kivipelto; Francesca Mangialasche; Tiia Ngandu
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

10.  ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Authors:  Jeffrey L Cummings; Sharon Cohen; Christopher H van Dyck; Mark Brody; Craig Curtis; William Cho; Michael Ward; Michel Friesenhahn; Christina Rabe; Flavia Brunstein; Angelica Quartino; Lee A Honigberg; Reina N Fuji; David Clayton; Deborah Mortensen; Carole Ho; Robert Paul
Journal:  Neurology       Date:  2018-04-25       Impact factor: 9.910

View more
  3 in total

1.  Treadmill Exercise Improves PINK1/Parkin-Mediated Mitophagy Activity Against Alzheimer's Disease Pathologies by Upregulated SIRT1-FOXO1/3 Axis in APP/PS1 Mice.

Authors:  Na Zhao; Xianliang Zhang; Baixia Li; Jing Wang; Chenfei Zhang; Bo Xu
Journal:  Mol Neurobiol       Date:  2022-10-20       Impact factor: 5.682

Review 2.  Are mitophagy enhancers therapeutic targets for Alzheimer's disease?

Authors:  Jangampalli Adi Pradeepkiran; Ashly Hindle; Sudhir Kshirsagar; P Hemachandra Reddy
Journal:  Biomed Pharmacother       Date:  2022-04-04       Impact factor: 7.419

Review 3.  Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets.

Authors:  Stefano Thellung; Alessandro Corsaro; Irene Dellacasagrande; Mario Nizzari; Martina Zambito; Tullio Florio
Journal:  Front Neurosci       Date:  2022-09-06       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.